Neuropeptide Y acts in the paraventricular nucleus to suppress sympathetic nerve activity and its baroreflex regulation

Priscila A. Cassaglia, Zhigang Shi, Baoxin Li, Wagner L. Reis, Nicholas M. Clute-Reinig, Javier E. Stern, Virginia Brooks

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Neuropeptide Y (NPY), a brain neuromodulator that has been strongly implicated in the regulation of energy balance, also acts centrally to inhibit sympathetic nerve activity (SNA); however, the site and mechanism of action are unknown. In chloralose-anaesthetized female rats, nanoinjection of NPY into the paraventricular nucleus of the hypothalamus (PVN) dose-dependently suppressed lumbar SNA (LSNA) and its baroreflex regulation, and these effects were blocked by prior inhibition of NPY Y1 or Y5 receptors. Moreover, PVN injection of Y1 and Y5 receptor antagonists in otherwise untreated rats increased basal and baroreflex control of LSNA, indicating that endogenous NPY tonically inhibits PVN presympathetic neurons. The sympathoexcitation following blockade of PVN NPY inhibition was eliminated by prior PVN nanoinjection of the melanocortin 3/4 receptor inhibitor SHU9119. Moreover, presympathetic neurons, identified immunohistochemically using cholera toxin b neuronal tract tracing from the rostral ventrolateral medulla (RVLM), express NPY Y1 receptor immunoreactivity, and patch-clamp recordings revealed that both NPY and α-melanocyte-stimulating hormone (α-MSH) inhibit and stimulate, respectively, PVN-RVLM neurons. Collectively, these data suggest that PVN NPY inputs converge with α-MSH to influence presympathetic neurons. Together these results identify endogenous NPY as a novel and potent inhibitory neuromodulator within the PVN that may contribute to changes in SNA that occur in states associated with altered energy balance, such as obesity and pregnancy.

Original languageEnglish (US)
Pages (from-to)1655-1675
Number of pages21
JournalJournal of Physiology
Volume592
Issue number7
DOIs
StatePublished - Apr 1 2014

Fingerprint

Baroreflex
Paraventricular Hypothalamic Nucleus
Neuropeptide Y
Hypothalamus
Melanocyte-Stimulating Hormones
Neurons
Neurotransmitter Agents
Receptor, Melanocortin, Type 3
Receptor, Melanocortin, Type 4
Chloralose
Cholera Toxin
Obesity
Pregnancy
Injections
Brain

ASJC Scopus subject areas

  • Physiology
  • Medicine(all)

Cite this

Neuropeptide Y acts in the paraventricular nucleus to suppress sympathetic nerve activity and its baroreflex regulation. / Cassaglia, Priscila A.; Shi, Zhigang; Li, Baoxin; Reis, Wagner L.; Clute-Reinig, Nicholas M.; Stern, Javier E.; Brooks, Virginia.

In: Journal of Physiology, Vol. 592, No. 7, 01.04.2014, p. 1655-1675.

Research output: Contribution to journalArticle

Cassaglia, Priscila A. ; Shi, Zhigang ; Li, Baoxin ; Reis, Wagner L. ; Clute-Reinig, Nicholas M. ; Stern, Javier E. ; Brooks, Virginia. / Neuropeptide Y acts in the paraventricular nucleus to suppress sympathetic nerve activity and its baroreflex regulation. In: Journal of Physiology. 2014 ; Vol. 592, No. 7. pp. 1655-1675.
@article{32cc9f88fda1409294b63e27ec490c24,
title = "Neuropeptide Y acts in the paraventricular nucleus to suppress sympathetic nerve activity and its baroreflex regulation",
abstract = "Neuropeptide Y (NPY), a brain neuromodulator that has been strongly implicated in the regulation of energy balance, also acts centrally to inhibit sympathetic nerve activity (SNA); however, the site and mechanism of action are unknown. In chloralose-anaesthetized female rats, nanoinjection of NPY into the paraventricular nucleus of the hypothalamus (PVN) dose-dependently suppressed lumbar SNA (LSNA) and its baroreflex regulation, and these effects were blocked by prior inhibition of NPY Y1 or Y5 receptors. Moreover, PVN injection of Y1 and Y5 receptor antagonists in otherwise untreated rats increased basal and baroreflex control of LSNA, indicating that endogenous NPY tonically inhibits PVN presympathetic neurons. The sympathoexcitation following blockade of PVN NPY inhibition was eliminated by prior PVN nanoinjection of the melanocortin 3/4 receptor inhibitor SHU9119. Moreover, presympathetic neurons, identified immunohistochemically using cholera toxin b neuronal tract tracing from the rostral ventrolateral medulla (RVLM), express NPY Y1 receptor immunoreactivity, and patch-clamp recordings revealed that both NPY and α-melanocyte-stimulating hormone (α-MSH) inhibit and stimulate, respectively, PVN-RVLM neurons. Collectively, these data suggest that PVN NPY inputs converge with α-MSH to influence presympathetic neurons. Together these results identify endogenous NPY as a novel and potent inhibitory neuromodulator within the PVN that may contribute to changes in SNA that occur in states associated with altered energy balance, such as obesity and pregnancy.",
author = "Cassaglia, {Priscila A.} and Zhigang Shi and Baoxin Li and Reis, {Wagner L.} and Clute-Reinig, {Nicholas M.} and Stern, {Javier E.} and Virginia Brooks",
year = "2014",
month = "4",
day = "1",
doi = "10.1113/jphysiol.2013.268763",
language = "English (US)",
volume = "592",
pages = "1655--1675",
journal = "Journal of Physiology",
issn = "0022-3751",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Neuropeptide Y acts in the paraventricular nucleus to suppress sympathetic nerve activity and its baroreflex regulation

AU - Cassaglia, Priscila A.

AU - Shi, Zhigang

AU - Li, Baoxin

AU - Reis, Wagner L.

AU - Clute-Reinig, Nicholas M.

AU - Stern, Javier E.

AU - Brooks, Virginia

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Neuropeptide Y (NPY), a brain neuromodulator that has been strongly implicated in the regulation of energy balance, also acts centrally to inhibit sympathetic nerve activity (SNA); however, the site and mechanism of action are unknown. In chloralose-anaesthetized female rats, nanoinjection of NPY into the paraventricular nucleus of the hypothalamus (PVN) dose-dependently suppressed lumbar SNA (LSNA) and its baroreflex regulation, and these effects were blocked by prior inhibition of NPY Y1 or Y5 receptors. Moreover, PVN injection of Y1 and Y5 receptor antagonists in otherwise untreated rats increased basal and baroreflex control of LSNA, indicating that endogenous NPY tonically inhibits PVN presympathetic neurons. The sympathoexcitation following blockade of PVN NPY inhibition was eliminated by prior PVN nanoinjection of the melanocortin 3/4 receptor inhibitor SHU9119. Moreover, presympathetic neurons, identified immunohistochemically using cholera toxin b neuronal tract tracing from the rostral ventrolateral medulla (RVLM), express NPY Y1 receptor immunoreactivity, and patch-clamp recordings revealed that both NPY and α-melanocyte-stimulating hormone (α-MSH) inhibit and stimulate, respectively, PVN-RVLM neurons. Collectively, these data suggest that PVN NPY inputs converge with α-MSH to influence presympathetic neurons. Together these results identify endogenous NPY as a novel and potent inhibitory neuromodulator within the PVN that may contribute to changes in SNA that occur in states associated with altered energy balance, such as obesity and pregnancy.

AB - Neuropeptide Y (NPY), a brain neuromodulator that has been strongly implicated in the regulation of energy balance, also acts centrally to inhibit sympathetic nerve activity (SNA); however, the site and mechanism of action are unknown. In chloralose-anaesthetized female rats, nanoinjection of NPY into the paraventricular nucleus of the hypothalamus (PVN) dose-dependently suppressed lumbar SNA (LSNA) and its baroreflex regulation, and these effects were blocked by prior inhibition of NPY Y1 or Y5 receptors. Moreover, PVN injection of Y1 and Y5 receptor antagonists in otherwise untreated rats increased basal and baroreflex control of LSNA, indicating that endogenous NPY tonically inhibits PVN presympathetic neurons. The sympathoexcitation following blockade of PVN NPY inhibition was eliminated by prior PVN nanoinjection of the melanocortin 3/4 receptor inhibitor SHU9119. Moreover, presympathetic neurons, identified immunohistochemically using cholera toxin b neuronal tract tracing from the rostral ventrolateral medulla (RVLM), express NPY Y1 receptor immunoreactivity, and patch-clamp recordings revealed that both NPY and α-melanocyte-stimulating hormone (α-MSH) inhibit and stimulate, respectively, PVN-RVLM neurons. Collectively, these data suggest that PVN NPY inputs converge with α-MSH to influence presympathetic neurons. Together these results identify endogenous NPY as a novel and potent inhibitory neuromodulator within the PVN that may contribute to changes in SNA that occur in states associated with altered energy balance, such as obesity and pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=84897089582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897089582&partnerID=8YFLogxK

U2 - 10.1113/jphysiol.2013.268763

DO - 10.1113/jphysiol.2013.268763

M3 - Article

VL - 592

SP - 1655

EP - 1675

JO - Journal of Physiology

JF - Journal of Physiology

SN - 0022-3751

IS - 7

ER -